The multimodal Munich Clinical Deep Phenotyping study to bridge the translational gap in severe mental illness treatment research

Lenka Krčmář, Iris Jäger, Emanuel Boudriot, Katharina Hanken, Vanessa Gabriel, Julian Melcher, Nicole Klimas, Fanny Dengl, Susanne Schmoelz, Pauline Pingen, Mattia Campana, Joanna Moussiopoulou, Vladislav Yakimov, Georgios Ioannou, Sven P. Wichert, Silvia DeJonge, Peter Zill, Boris Papazov, Valéria de Almeida, Sabrina Galinski, Nadja Gabellini, Genc Hasanaj, Matin Mortazavi, Temmuz Karali, Alexandra Hisch, Marcel S. Kallweit, Verena Meisinger, Lisa Löhrs, Karin Neumeier, Stephanie Behrens, Susanne Karch, Benedikt Schworm, Christoph Kern, Siegfried Priglinger, Berend Malchow, Johann Steiner, Alkomiet Hasan, Frank Padberg, Oliver Pogarell, Peter Falkai, Andrea Schmitt, Elias Wagner, Daniel Keeser, Florian J. RaabeFrontiers in Psychiatry 2023 · DOI

Abstract

The identification of cross-diagnostic and diagnosis-specific biotype-informed subgroups of patients and the translational dissection of those subgroups may help to pave the way toward precision medicine with artificial intelligence-supported tailored interventions and treatment. This aim is particularly important in psychiatry, a field where innovation is urgently needed because specific symptom domains, such as negative symptoms and cognitive dysfunction, and treatment-resistant symptoms in general are still difficult to treat.

Introduction: The Challenge of Heterogeneity in Psychiatry

Current psychiatric diagnostics for severe mental illnesses (SMI), such as schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD), rely on symptom clusters defined by the DSM-5 or ICD-10. However, these categories are biologically heterogeneous; two patients sharing a diagnosis may possess vastly different underlying neurobiology and treatment responses. This "translational gap" prevents laboratory findings from improving clinical outcomes. Approximately 25% of schizophrenia patients exhibit treatment resistance early in their illness, and domains like cognitive dysfunction remain difficult to address.

The Munich Clinical Deep Phenotyping (CDP) study is a large-scale initiative designed to move psychiatry beyond symptom-based diagnosis toward "biotype-informed" precision medicine. By collecting a massive, multimodal dataset, researchers aim to identify biological signatures that predict treatment response and guide personalized interventions.

Methodology: The Deep Phenotyping Approach

The CDP study adopts the Research Domain Criteria (RDoC) framework, shifting focus from traditional diagnoses to functional domains across a spectrum from normal to pathological. The "deep phenotyping" approach involves collecting an unusually broad array of data from every participant:

  • Clinical & Psychometric Assessment: Utilizing standardized scales (PANSS, CDSS, YMRS) and neurocognitive batteries (BACS).
  • Multimodal Brain Imaging (mMRI): Employs 3T scanners with protocols aligned with the Human Connectome Project (HCP), including structural MRI, DTI, resting-state/task-based fMRI, and magnetic resonance spectroscopy (MRS).
  • Electrophysiology: 32-channel EEG (including P300 potentials) and Transcranial Magnetic Stimulation (TMS) to assess cortical excitability.
  • Retinal Imaging: Optical Coherence Tomography (OCT) and electroretinography (ERG) serve as non-invasive "windows to the brain" to study CNS microvasculature and neurodegeneration.
  • Biobanking: Collection of blood and CSF for transcriptomics and proteomics, alongside the generation of human-induced pluripotent stem cells (hiPSCs).

Cohort and Data Integration

The initiation phase of the CDP cohort includes 381 participants: 194 individuals with SMI (primarily schizophrenia spectrum and bipolar disorders) and 187 age- and gender-matched healthy controls (HC). A key strength of the CDP study is its integration with previous cohorts, including the MIMICSS imaging study and a dedicated hiPSC cohort.

Overlap between the CDP cohort and previous longitudinal/translational subcohorts.

This integration allows for robust longitudinal and translational analysis, connecting clinical phenotypes with cellular models.

Key Insights: From Biotypes to "Clinical Trials in a Dish"

The CDP study introduces several innovative concepts to psychiatric research:

  • Transdiagnostic Biotypes: Identifying biological patterns (e.g., circuit dysfunctions) that appear across traditional diagnostic boundaries.
  • The Retina as a Biomarker: Preliminary results suggest thinner inner retinal layers in schizophrenia spectrum disorders, highlighting the retina's potential as a high-resolution biomarker.
  • Patient-Specific Cell Models: By biobanking hiPSCs from deeply phenotyped patients, researchers can create "clinical trials in a dish," testing molecular pathways and screening drugs in vitro before clinical application.
  • Global Compatibility: By aligning with HCP protocols and RDoC units, the CDP data is compatible with international efforts like ENIGMA and the UK Biobank.

Feasibility and Participation

A primary achievement of the CDP study is the demonstration of feasibility. Over the first two years, the team successfully recruited nearly 400 participants and maintained high participation rates across demanding modalities.

Participation rates across different diagnostic modalities.

Data indicates no statistically significant difference in the willingness of patients versus healthy controls to participate in most examinations, including EEG, OCT, and blood sampling. While MRI participation was slightly lower in patients (p=0.06), the overall data collection remains robust.

Limitations and Future Directions

While the current sample of 381 is significant, larger datasets are required for high-dimensional "big data" analytics to identify rare biotypes. Currently, much of the data is cross-sectional, though longitudinal follow-ups (six months to two years) are underway to capture biological changes over time. Additionally, disentangling the effects of long-term medication from disease pathology remains a challenge, which the study aims to address by recruiting drug-naïve and first-episode patients. The next phase involves integrating "omics" data with clinical and imaging phenotypes for AI-supported patient stratification.

Summary updated

Abstract

The identification of cross-diagnostic and diagnosis-specific biotype-informed subgroups of patients and the translational dissection of those subgroups may help to pave the way toward precision medicine with artificial intelligence-supported tailored interventions and treatment. This aim is particularly important in psychiatry, a field where innovation is urgently needed because specific symptom domains, such as negative symptoms and cognitive dysfunction, and treatment-resistant symptoms in general are still difficult to treat.
BibTeX
@inproceedings{krcmar2023multimodal,
  author = {Lenka Krčmář and Iris Jäger and Emanuel Boudriot and Katharina Hanken and Vanessa Gabriel and Julian Melcher and Nicole Klimas and Fanny Dengl and Susanne Schmoelz and Pauline Pingen and Mattia Campana and Joanna Moussiopoulou and Vladislav Yakimov and Georgios Ioannou and Sven P. Wichert and Silvia DeJonge and Peter Zill and Boris Papazov and Valéria de Almeida and Sabrina Galinski and Nadja Gabellini and Genc Hasanaj and Matin Mortazavi and Temmuz Karali and Alexandra Hisch and Marcel S. Kallweit and Verena Meisinger and Lisa Löhrs and Karin Neumeier and Stephanie Behrens and Susanne Karch and Benedikt Schworm and Christoph Kern and Siegfried Priglinger and Berend Malchow and Johann Steiner and Alkomiet Hasan and Frank Padberg and Oliver Pogarell and Peter Falkai and Andrea Schmitt and Elias Wagner and Daniel Keeser and Florian J. Raabe},
  title = {{The multimodal Munich Clinical Deep Phenotyping study to bridge the translational gap in severe mental illness treatment research}},
  booktitle = {Frontiers in Psychiatry},
  year = {2023},
  doi = {10.3389/fpsyt.2023.1179811},
}
Figure